Dezeen Showroom: Italian brand Fiandre aimed to create a "vocabulary of surfaces" with the Lexicon tile collection, featuring eight high-tech stone- and marble-inspired designs. Both atmospheric, ...

A town's major shopping centre has reportedly been bought by an investment firm for about £150m. US-based Realty Income bought The Lexicon in Bracknell from previous owners Schroder Capital UK Real ...

THE WOODLANDS, Texas, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended September 30, 2025, and provided an ...

We may earn an affiliate commission when you buy through our links. Guitar effects technology is continually making leaps and bounds. There's no shortage of increasingly good-sounding all-in-one ...

Lexicon has pivoted back to a research-driven biotech model, abandoning internal drug marketing to focus on clinical development and out-licensing. Pilavapadin's upcoming Phase II readout is critical, ...

A new technical paper titled “Memory Prefetching Evaluation of Scientific Applications on A Modern HPC Arm-based Processor” was published by researchers at Jülich Supercomputing Centre and KTH Royal ...

THE WOODLANDS, Texas — A Houston-area pharmaceutical company has struck a billion-dollar deal with the seller of Ozempic for a potential drug also aiming to combat obesity. Lexicon Pharmaceuticals Inc ...

Lexicon's stock rose 60% after securing a potential $1 billion deal with Novo Nordisk for the preclinical obesity drug LX9851. The company abandoned its underperforming heart failure drug and shifted ...

During the last three months, 6 analysts shared their evaluations of Lexicon Pharmaceuticals (NASDAQ:LXRX), revealing diverse outlooks from bullish to bearish. The following table summarizes their ...

March 28 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab is licensing Lexicon Pharmaceuticals' (LXRX.O), opens new tab experimental obesity drug in a deal worth up to $1 billion, the Danish ...

Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) stock is trading higher on Friday. Penny stock Lexicon Pharmaceuticals entered into an exclusive license agreement with Novo Nordisk A/S (NYSE:NVO) on Friday ...

Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attracted Novo Nordisk. The Danish drugmaker is betting $75 million in upfront and near-term milestone payments to secure ...